<a href="https://www.fiercebiotech.com/biotech/tortugas-comes-out-its-shell-106m-fund-4-phase-2-stage-neuro-drugs" hreflang="en">Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia</a>
Tortugas Neuroscience, a new biotech startup led by former Sage Therapeutics executives, has secured $106 million to advance four phase 2 neuro drugs licensed from Eisai and Hansoh Pharmaceutical, targeting conditions such as schizophrenia and tinnitus. The company aims to develop small-molecule therapeutics with clear regulatory pathways and strong market differentiation.
Tortugas Neuroscience's launch with $106 million to advance four phase 2-stage neuro drugs, particularly the D2/D3 partial agonist for schizophrenia and a GABA modulator for tinnitus, highlights a strategic focus on developing small molecule therapies with "derisked mechanisms of action" for clear regulatory paths. This approach, emphasizing oral formulations for large, well-defined indications, could position Tortugas as a significant player in neurology, offering potential investment opportunities or partnerships for those tracking advancements in neuropharmaceuticals and digital therapeutics.